HyperRAB S/D, KedRab (rabies immune globulin, human (RIG)) …
网页Medscape - Rabies prophylaxis dosing for HyperRAB S/D, KedRab (rabies immune globulin, human (RIG)), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy...
Safety and efficacy results of simulated post-exposure prophylaxis …
网页2019年9月24日 · We conducted a clinical trial to assess the safety and putative efficacy of an additional human rabies immune globulin (HRIG; KEDRAB) versus an older product (Comparator, HyperRAB S/D® [Grifols]) and determine whether HRIG interferes with development of endogenous antibodies versus Comparator, when each is given with an active rabies vaccine.
Safety and efficacy results of simulated post-exposure ... - PubMed
网页We conducted a clinical trial to assess the safety and putative efficacy of an additional human rabies immune globulin (HRIG; KEDRAB) versus an older product (Comparator, HyperRAB S/D® [Grifols]) and determine whether HRIG interferes with development of endogenous antibodies versus Comparator, when ….
New, More Potent Rabies Treatment Now Available - ACEP Now
网页2018年9月25日 · New, More Potent Rabies Treatment Now Available. HyperRAB 300 IU/mL is a higher-potency formulation of a previously Food and Drug Administration–approved rabies immune globulin (RIG; human), HyperRAB S/D, also available as 1,500 IU/10 mL. 1 The original HyperRAB S/D is available as 300 IU/2 mL and 1,500 IU/10 mL.
HyperRAB® Postexposure Treatment for Rabies | Official Site
网页Provide immediate protection with HyperRAB. HyperRAB is an HRIG that provides rapid immune coverage, indicated for postexposure prophylaxis (PEP), along with rabies vaccine, for all persons suspected of exposure to rabies. 1,6 Review the CDC guidelines for PEP.
Rabies Immune Globulin (Intramuscular Route) Description and …
网页2024年2月1日 · HyperRAB SD; Imogam Rabies-HT; Kedrab; Descriptions. Rabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. It works by giving your body the antibodies it needs to protect it against the rabies virus. This is called passive protection.
Safety and efficacy in the pediatric population - National Center …
网页2022年4月19日 · In 2017, Kedrion Biopharma introduced KEDRAB® Human Rabies Immune Globulin (HRIG) to the US market for the prevention of rabies infections as a component of post-exposure prophylaxis (PEP). At that time there were two other HRIG products on the US market, Imogam® Rabies-HT and HyperRab® S/D.
Safety and efficacy of rabies immunoglobulin in pediatric patients …
网页2021年2月9日 · We report the safety, efficacy, and immunogenicity of a phase 4, prospective, 2-center, open-label, single-arm clinical trial evaluating human rabies immunoglobulin (HRIG150; KEDRAB 150 IU/mL) as part of PEP in patients (aged <17) with suspected or confirmed rabies exposure, where PEP was indicated.
Commentary on the implications of safety and efficacy studies in ...
网页The most common treatment emergent adverse events (TEAE) were injection-site pain. Currently there are 3 HRIG products on the US market, KEDRAB®, HyperRab® and Imogam® Rabies HT, but only KEDRAB® has published safety and efficacy data in a pediatric population.
网页WG Conclusions about KedrabTM and HyperRab®. Safety and efficacy: Non-inferiority to previously licensed products. After review of data, WG concluded. “Newly licensed products” are not “new”. Preference is for no preferential recommendation of a RIG product.
- 某些结果已被删除
跳至内容